BRAF anticorps (pThr439)

N° du produit ABIN358271

L’anticorps Lapin Polyclonal anti-BRAF a été validé pour EIA. Il convient pour détecter BRAF dans des échantillons de Humain.

Aperçu rapide pour BRAF anticorps (pThr439) (ABIN358271)

Antigène: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BRAF est non-conjugé

Application: Enzyme Immunoassay (EIA)

Détail du produit anti-BRAF anticorps

Épitope: pThr439

Specificité: This antibody detects BRAF pThr439.

Purification: Protein A Affinity Chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with peptides. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.

Immunogène: This antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Thr439 of human BRAF.

Isotype: Ig Fraction

Information d'application

Indications d'application: ELISA: 1/1,000. Dot Blot: 1/100-1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) Sodium Azide as preservative.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Détails sur BRAF

Antigène: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Sujet: BRAF is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It may play a role in the postsynaptic responses of hippocampal neuron. Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome), also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.Synonyms: B-Raf proto-oncogene serine/threonine-protein kinase, BRAF, BRAF1, RAFB1, p94, v-Raf murine sarcoma viral oncogene homolog B1

Poids moléculaire: 84437 Da

ID gène: 673, 9606

UniProt: P15056

Pathways: Signalisation MAPK, Signalisation RTK, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy